{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:02:39Z","timestamp":1792180959558,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) cancers exhibit high immunogenicity and are highly responsive to immune checkpoint inhibitors. In patients with locally advanced dMMR\/MSI-H colorectal cancer (CRC), neoadjuvant immunotherapy (NIT) has demonstrated unprecedented pathological complete response (pCR) rates, suggesting nonoperative management strategies may be possible. There remains a discrepancy between radiological assessment and pathological responses to NIT in CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of studies published between February 2015 and February 2025 to determine if radiological and pathological assessments following neoadjuvant immune checkpoint inhibitor therapy (NIT) were consistent in patients with non-metastatic dMMR\/MSI-H CRC. Using PubMed, Embase, and Web of Science, the literature was retrieved, with inclusion criteria focusing on studies that reported both imaging data and pathological results. A random-effects model was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup analyses were conducted based on tumor location (colon versus rectum) and type of response (cCR versus pCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 12 studies, 396 patients were included. A total rate of 59.6% discordance was found between radiological and pathological responses. Compared to rectal cancer patients (34.9%), colon cancer patients exhibited a significantly higher rate of discordance (64.2%). A total of 238 patients with confirmed pCR were incorrectly diagnosed as having residual disease on radiological assessment (OR = 61.41; 95% CI: 10.05\u2013375.27;P &amp;lt; 0.00001). A high level of heterogeneity was observed across studies (I2 = 85%), but no publication bias was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In dMMR\/MSI-H CRC, radiologic assessment alone cannot reliably assess the efficacy of NIT, particularly in colon cancer. It should be integrated with additional modalities\u2014such as endoscopic evaluation and biomarker analysis\u2014to ensure an accurate appraisal of treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1680500","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:46:28Z","timestamp":1770623188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Discordance between radiological and pathological response to neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite instability-high colorectal cancer: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yilin","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/ijc.34647","article-title":"China special issue on gastrointestinal tumors-Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD-1 blockade: A post hoc analysis of the PICC phase II trial","volume":"153","author":"Cao","year":"2023","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative Management of Mismatch Repair-Deficient Tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7096","article-title":"Long-Term Outcomes of dMMR\/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment","volume":"22","author":"Yu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","article-title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study","volume":"25","author":"Yu","year":"2024","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.gastro.2024.08.003","article-title":"High Pathological Response Rate After Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer (NICHE-2 Study)","volume":"168","author":"Sallinen","year":"2025","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113356","article-title":"Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer","volume":"194","author":"Fox","year":"2023","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4240\/wjgs.v15.i2.222","article-title":"Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies","volume":"15","author":"Li","year":"2023","journal-title":"World J Gastrointest Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182299","article-title":"Locally advanced rectal cancer with dMMR\/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913483","article-title":"Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR\/MSI-H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466497","article-title":"Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR\/MSI-H locally advanced colorectal cancer","volume":"15","author":"Deng","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejca.2022.07.016","article-title":"Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR\/MSI-H rectal cancer: A multicentre cohort study","volume":"174","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2022.7060","article-title":"Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer","volume":"21","author":"Xiao","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1097\/DCR.0000000000003290","article-title":"Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR\/MSI-H Status","volume":"67","author":"Li","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"B23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clcc.2024.07.001","article-title":"Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy","volume":"24","author":"Li","year":"2025","journal-title":"Clin Colorectal Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1391038","article-title":"A watch-and-wait approach for metachronous multiple colon cancer following neoadjuvant immunotherapy: a case report","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/SLA.0000000000006443","article-title":"Introducing Neoadjuvant Immunotherapy for Colorectal Cancer:\nAdvancing the Frontier","volume":"281","author":"Orhan","year":"2025","journal-title":"Ann Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.6004\/jnccn.2022.7071","article-title":"Prevalent Pseudoprogression and Pseudoresidue in Patients With\nRectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors","volume":"21","author":"Xie","year":"2023","journal-title":"J Natl\nCompr Canc Netw"},{"key":"B28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune\nsystem","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","article-title":"Neoadjuvant botensilimab plus balstilimab response pattern in\nlocally advanced mismatch repair proficient colorectal cancer","volume":"42","author":"Kasi","year":"2023","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA8","article-title":"Results from a phase 1a\/1b study of botensilimab (BOT), a novel innate\/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)","volume":"41","author":"El-Khoueiry","year":"2023","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant Pembrolizumab in Localized Microsatellite Instability\nHigh\/Deficient Mismatch Repair Solid Tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15540","article-title":"Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer","volume":"41","author":"Abbosh","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1680500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:46:29Z","timestamp":1770623189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1680500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1680500"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1680500","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1680500"}}